OncoMed Presents Data From Phase 1b Trial of Demcizumab in Pancreatic Cancer at the 2015 ASCO Annual Meeting
June 01, 2015 09:00 ET
|
OncoMed Pharmaceuticals, Inc.
Demcizumab plus Abraxane and Gemcitabine in Advanced Pancreatic Cancer Results in 50% Response Rate, Progression-Free Survival of 9.0 Months and Overall Survival of 10.1 Months
Randomized Phase 2...
OncoMed to Present at Upcoming Investment Conferences
May 28, 2015 16:30 ET
|
OncoMed Pharmaceuticals, Inc.
REDWOOD CITY, Calif., May 28, 2015 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cell (CSC) and...